共 50 条
What's New in Cutaneous T-Cell Lymphoma-Associated Pruritus
被引:1
|作者:
Soares, Georgia Biazus
[1
]
Guitart, Joan
[2
]
Yosipovitch, Gil
[1
,3
]
机构:
[1] Univ Miami, Miami Itch Ctr, Miller Sch Med, Dr Phillip Frost Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL USA
[3] 5555 Ponce Leon, Coral Gables, FL 33146 USA
关键词:
QUALITY-OF-LIFE;
MYCOSIS-FUNGOIDES;
SEZARY-SYNDROME;
MULTICENTER-TRIAL;
OPEN-LABEL;
TOPICAL CORTICOSTEROIDS;
MONOCLONAL-ANTIBODY;
RECEPTOR ANTAGONIST;
PHASE-2;
TRIAL;
KALLIKREIN;
D O I:
10.1007/s40257-023-00823-2
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100206 ;
摘要:
Cutaneous T-cell lymphomas are a heterogenous group of lymphomas that cause various skin manifestations. Severe pruritus occurs frequently in cutaneous T-cell lymphoma and negatively impacts patients' quality of life. The pathophysiology of cutaneous T-cell lymphoma-associated itch is complex and involves various immune cells, inflammatory cytokines, and neuroimmune interactions. Treating cutaneous T-cell lymphoma pruritus can be challenging, and there have been few randomized controlled studies evaluating the use of antipruritic treatments in these patients. Systemic therapies targeting the disease have also been shown to have some antipruritic effects. Furthermore, although biologic therapy has revolutionized the treatment of other pruritic skin conditions, the use of biologics in cutaneous T-cell lymphoma remains controversial.
引用
收藏
页码:67 / 77
页数:11
相关论文